Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 2.69 +0.04 (1.51%)
price chart
Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life ...
In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc. SNSS, +1.51% describes how his company is making clinical progress toward developing a new treatment for this devastating disease, ...
Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS)
Despite a decrease in cash flow of 20.20%, SUNESIS PHARMACEUTICALS INC is in line with the industry average cash flow growth rate of -24.34%.
Related articles »  
Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 9% on the day.
Related articles »  
Sunesis Pharmaceuticals Inc. (SNSS) is Trading Higher on Unusual Volume for ...
Sunesis Pharmaceuticals Inc. (SNSS) experienced unusually high volume on Apr. 15, as the stock gained 3.64% to a closing price of $2.85.
BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will ...
BTIG initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) Monday with a Buy rating and $5.50 price target.
Related articles »  
UPDATE: UBS Starts Sunesis Pharmaceuticals Inc. (SNSS) at Buy
UBS initiated coverage on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) with a Buy rating and a price target of $14.00. Analyst Andrew Peters said, "Key points from our analysis: [1] SNSS provides an exceptionally high risk/reward ahead of the ph3 VALOR ...
Related articles »  
Sunesis Pharmaceuticals: Battle Cancer and Enhance Investments
The Life Sciences Report interviews Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals, Inc. The Life Sciences Report: Daniel, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has been around for more than 15 years. How does the ...
Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth
Sunesis Pharmaceuticals, Inc.'s (NASDAQ: SNSS) failed cancer drug vosaroxin offers no reason for investors to give up hope on other companies' potential cures, an analyst said Tuesday.
An Insight Into Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)  Inside Trade
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin ...  MarketWatch
Related articles »  
UPDATE: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals (SNSS) to Buy ...
Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) gained Wednesday after being upgraded to Buy from Hold with a price target of $4 (from $2) by analyst Mara Goldstein of Cantor Fitzgerald.
3 Buzzing Pharma Stocks: Second Sight Medical Products Inc (EYES), Sunesis ...  NIS
Related articles »  
Is This the Sunesis Resurrection?
In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately had catastrophic results for the stock price ...
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of ...
Related articles »